HIPEC application potential in the treatment of extensive carcinomatosis in ovarian cancer (retrospective study)

Background. The high prevalence of advanced forms of cancer currently requires new treatment approaches. Only modern high-tech surgical procedures can provide means for improving the results of treatment.

The aim. To study the results of treatment of patients with ovarian cancer with symptoms of peritoneal carcinomatosis using the HIPEC (Hyperthermic IntraPEritoneal Chemotherapy) method.

Materials and methods. The study was conducted in Irkutsk Regional Cancer Center and included 88 patients. They were divided into 2 groups: group 1 – primary cytoreductive surgery (CRS) with the HIPEC method (41 patients); group 2 – primary cytoreductive surgery (47 patients). The most important criterion was the peritoneal cancer index (PCI). If the PCI was ≤ 14, we chose cytoreductive surgery with or without HIPEC.

Results. PCI analysis showed differences in its values between the study groups (CRS – 10.17 ± 0.952; CRS + HIPEC – 12.93 ± 0.744; p = 0.002). There was an increase in length of stay in patients who underwent major surgeries in combination with HIPEC (21.8 ± 0.9 days versus 14.5 ± 0.6 days in the CRS group; p = 0.001). The CRS + HIPEC group had a longer duration of surgery (394.88 ± 19.935 min vs. 172.98 ± 11.514 min in the CRS group; p = 0.001). There was an increase in the overall percentage of postoperative complications in the CRS + HIPEC group – up to 26.8 % without statistically significant differences with the CRS group – 8.5 % (p = 0.082). The median time of relapse onset in the CRS + HIPEC group was 26 ± 4.3 months, while in the CRS group it was 18 ± 2.6 months.

Conclusion. Using HIPEC method has proven its significance in increasing diseasefree survival.

1. Kaprin AD, Starinsky VV, Shakhzadova AO. The state of cancer care for the population of Russia in 2022. Moscow; 2023. (In Russ.).

2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394-424. doi: 10.3322/caac.21492

3. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021; 155(Suppl 1): 61-85. doi: 10.1002/ijgo.13878

4. Nougaret S, Addley HC, Colombo PE, Fujii S, Al Sharif SS, Tirumani SH, et al. Ovarian carcinomatosis: How the radiologist can help plan the surgical approach. Radiographics. 2012; 32(6): 1775-1800; discussion 1800-1803. doi: 10.1148/rg.326125511

5. Antonio CCP, Alida GG, Elena GG, Rocío GS, Jerónimo MG, Luis ARJ, et al. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: A phase 3 clinical trial. Ann Surg Oncol. 2022; 29(4): 2617-2625. doi: 10.1245/s10434-021-11087-7

6. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995; 221(1): 29-42. doi: 10.1097/00000658-199501000-00004

7. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018; 378(3): 230-240. doi: 10.1056/NEJMoa1708618

8. Spiliotis J, Iavazzo C, Fotiou A, Kopanakis N, Terra A, Efstathiou E, et al. Upfront or intermediate treatment of advanced ovarian cancer patients with cytoreduction plus HIPEC: Results of a retrospective study. J Surg Oncol. 2021; 123(2): 630-637. doi: 10.1002/jso.26280

9. Rosendahl M, Harter P, Bjørn SF, Høgdall C. Specific regions, rather than the entire peritoneal carcinosis index, are predictive of complete resection and survival in advanced epithelial ovarian cancer. Int JGynecol Cancer. 2018; 28(2): 316-322. doi: 10.1097/IGC.0000000000001173

10. Iavazzo C, Fotiou A, Psomiadou V, Lekka S, Katsanos D, Spiliotis J. Small bowel PCI score as a prognostic factor of ovarian cancer patients undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), a retrospective analysis of 130 patients. Indian J Surg Oncol. 2021; 12(2): 258-265. doi: 10.1007/s13193-021-01304-w

11. Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, Di Silvestro PA, et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2019; 37(16): 1380-1390. doi: 10.1200/JCO.18.01568

12. Zakharenko AA, Belyaev MA, Trushin AA, Zaytsev DA, Ten OA, Natkha AS, et al. Comparative analysis of the efficacy of various methods of regional intraperitoneal chemotherapy. Problems in Oncology. 2018; 64(2): 266-271. (In Russ.).

13. Helderman RFCPA, Löke DR, Kok HP, Oei AL, Tanis PJ, Franken NAPK, et al. Variation in clinical application of hyperthermic intraperitoneal chemotherapy: A review. Cancers (Basel). 2019; 11(1): 78. doi: 10.3390/cancers11010078

14. Sugarbaker PH, Van der Speeten K, Stuart OA. Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. World J Gastrointest Oncol. 2010; 2(1): 19-30. doi: 10.4251/wjgo.v2.i1.19

15. de Bree E, Tsiftsis DD. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: From laboratory bench to bedside. Recent Results Cancer Res. 2007; 169: 53-73. doi: 10.1007/978-3-540-30760-0_5

16. Aronson SL, Lopez-Yurda M, Koole SN, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): Final survival analysis of a randomised, controlled, phase 3 trial. Lancet Oncol. 2023; 24(10): 1109-1118. doi: 10.1016/S1470-2045(23)00396-0

17. Muñoz-Casares FC, Medina-Fernández FJ, ArjonaSánchez Á, Casado-Adam Á, Sánchez-Hidalgo JM, Rubio MJ, et al. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center. Eur J Surg Oncol. 2016; 42(2): 224-233. doi: 10.1016/j.ejso.2015.11.006

18. Filis P, Mauri D, Markozannes G, Tolia M, Filis N, Tsilidis K. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: A systematic review and meta-analysis of randomized trials. ESMO Open. 2022; 7(5): 100586. doi: 10.1016/j.esmoop.2022.100586